Mineralys Therapeutics (MLYS) Other financing activities (2024 - 2026)
Quarterly results put Other financing activities at $1000.0 for Q1 2026, down 90.0% from a year ago — trailing twelve months through Mar 2026 was $382000.0 (changed 0.0% YoY), and the annual figure for FY2025 was $391000.0, down 10.11%.
Mineralys Therapeutics has reported Other financing activities over the past 3 years, most recently at $1000.0 for Q1 2026.
- Other financing activities reached $1000.0 in Q1 2026 per MLYS's latest filing, down from $305000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $305000.0 in Q4 2025 and bottomed at $1000.0 in Q1 2026.
- Median Other financing activities over the past 3 years was $47000.0 (2024), compared with a mean of $91888.9.
- The largest annual shift saw Other financing activities soared 548.94% in 2025 before it tumbled 90.0% in 2026.
- Over 3 years, Other financing activities stood at $47000.0 in 2024, then skyrocketed by 548.94% to $305000.0 in 2025, then crashed by 99.67% to $1000.0 in 2026.
- Business Quant data shows Other financing activities for MLYS at $1000.0 in Q1 2026, $305000.0 in Q4 2025, and $29000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Mineralys Therapeutics | 2.50 Bn | 2.50 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Dec 31, 2025 | 305,000.00 |
| Dec 31, 2025 | 305,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 47,000.00 |
| Jun 30, 2025 | 47,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Sep 30, 2024 | 41,000.00 |
| Sep 30, 2024 | 41,000.00 |
| Jun 30, 2024 | 284,000.00 |
| Jun 30, 2024 | 284,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Mar 31, 2024 | 63,000.00 |